DXRX logo element
DXRX logo element
Coming Soon

PD-L1 testing: Cross indications

Wed Aug 24 2022

The aim of this Lab Talk is to provide an overview of PD-L1 testing in Breast Cancer, Urothelial Cancer, Gastric and Esophageal Cancer to highlight the principles of cancer immunotherapy, with a focus on checkpoint inhibitors targeting PD-L1.

Lab Talks: PD-L1 testing cross indications_promotional_graphic

Date and time: September 2022, 19th. 3pm CET

Duration: 1 hour 15mins (total)

Agenda:

  • Diaceutics Intro & Housekeeping – Antonio Capece (5 mins)
  • PD-L1 testing in TNBC – Prof. Nicola Fusco (15 mins)
  • Q&A session – All participants (5 mins)
  • PD-L1 in Urothelial cancer: what’s new - Dr. Matthew Evans (15 mins)
  • Q&A session – All participants (5 mins)
  • PD-L1 in Gastric and Esophageal cancer: present and future - Dr. Mar Iglesias Coma (15 mins)
  • Q&A session – All participants (5 mins)
  • Q&A session – Final discussion – All participants (10 min)

Note: This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology (ASCP) as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program and any other boards that recognize this credit.

We are in the process of uploading this recording.

Speaker biographies:

Prof. Nicola Fusco

Prof. Nicola Fusco

Prof. Nicola Fusco is the Director of the Biobank for Translational and Digital Medicine Unit, senior breast pathologist at the Division of Pathology, European Institute of Oncology (IEO), Milan, Italy, and Associate Professor of Pathology at Department of Oncology and Hemato-Oncology, University of Milan. He is a PI leading a multidisciplinary and international group of scientists focused on breast cancer predictive pathology, molecular pathology, immunopathology, and digital pathology. He is the recipient of national and international awards and research grants.

Dr. Matthew Evans

Dr. Matthew Evans

Dr Matthew Evans is a consultant Cellular Pathologist at both University Hospital Southampton NHS Foundation Trust and Black Country Pathology Services, where he specialises in biomarker, thoracic and gynaecological pathology. He was recently appointed Pathology Lead for the Central & South Genomic Medicine Service Alliance, and sits on the national Cancer Genomics Test Evaluation Working Group. He is particularly interested in the role of non-NGS testing technologies alongside genomic testing, and in biomarkers predicting response to immune checkpoint inhibitors. He has worked with industry in the roll-out of PD-L1 in multiple tumour types and trained several hundred pathologists globally in PD-L1 assessment.

Dr. Mar Iglesias Coma

Dr. Mar Iglesias Coma

Dr. Mar Iglesias Coma is the head of the Anatomical Pathology section at Hospital del Mar (Barcelona, Spain). She is specialized in gastrointestinal pathology. She is also associate professor at the Pompeu Fabra University and the current treasurer at the Spanish Society of Pathology (SEAP). Dr. Iglesias has participated in innovation projects related to digital pathology and biomarkers at Hospital del Mar, and is also involved in translational research projects with different research groups.